10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
14.04
+0.43 (3.16%)
At close: Dec 20, 2024, 4:00 PM
13.95
-0.09 (-0.64%)
After-hours: Dec 20, 2024, 4:20 PM EST
10x Genomics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for 10x Genomics stock have an average target of 25.14, with a low estimate of 14 and a high estimate of 46. The average target predicts an increase of 79.06% from the current stock price of 14.04.
Analyst Consensus: Buy
* Price targets were last updated on Nov 1, 2024.
Analyst Ratings
The average analyst rating for 10x Genomics stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 4 | 4 | 4 |
| Buy | 2 | 2 | 4 | 4 | 4 | 4 |
| Hold | 7 | 7 | 7 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 14 | 13 | 15 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $21 → $19 | Buy | Maintains | $21 → $19 | +35.33% | Nov 1, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $35 → $23 | Strong Buy | Maintains | $35 → $23 | +63.82% | Oct 30, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $16 → $14 | Strong Sell | Maintains | $16 → $14 | -0.28% | Oct 30, 2024 |
| JP Morgan | JP Morgan | Hold Maintains $20 → $14 | Hold | Maintains | $20 → $14 | -0.28% | Oct 30, 2024 |
| UBS | UBS | Hold Maintains $25 → $20 | Hold | Maintains | $25 → $20 | +42.45% | Oct 30, 2024 |
Financial Forecast
Revenue This Year
605.18M
from 618.73M
Decreased by -2.19%
Revenue Next Year
642.31M
from 605.18M
Increased by 6.14%
EPS This Year
-1.42
from -2.18
EPS Next Year
-1.23
from -1.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 631.0M | 693.0M | 766.9M | |||
| Avg | 605.2M | 642.3M | 702.7M | |||
| Low | 585.3M | 598.8M | 636.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.0% | 14.5% | 19.4% | |||
| Avg | -2.2% | 6.1% | 9.4% | |||
| Low | -5.4% | -1.1% | -0.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.23 | -0.64 | -0.04 | |||
| Avg | -1.42 | -1.23 | -0.81 | |||
| Low | -1.48 | -1.54 | -1.45 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.